FDA OK’s Trial of Transition’s AZD-103

Transition Therapeutics said Tuesday the U.S. Food and Drug Administration cleared a phase 1 trial of AZD-103 for Alzheimer’s.

Transition said it anticipates beginning the trial in September. Healthy volunteers will receive placebo or an escalating dose of AZD-103.

The company said a previous phase 1 trial of AZD-103 announced in April has completed enrollment. The company said in a statement that it plans to release data from the study in the near future.

A study in a transgenic mouse model of Alzheimer’s disease indicated AZD-103 reduced the accumulation of amyloid beta and amyloid beta plaques in the brain. The compound also reduced learning deficits in the mice.